CAR-T is a very exciting field, as we all know, and we will see not only new products, but most importantly, new indications. We are excited not only for the malignant indications, but also for the non-malignant ones like systemic lupus erythematosus or SLE that is presented also in this Congress. And we hope that during this process, we will be able to expand the population that will benefit from CAR-T therapy and also expand the physician community that knows about CAR-T and expand the facilities that will be able to perform the CAR-T therapy...
CAR-T is a very exciting field, as we all know, and we will see not only new products, but most importantly, new indications. We are excited not only for the malignant indications, but also for the non-malignant ones like systemic lupus erythematosus or SLE that is presented also in this Congress. And we hope that during this process, we will be able to expand the population that will benefit from CAR-T therapy and also expand the physician community that knows about CAR-T and expand the facilities that will be able to perform the CAR-T therapy. So this is a very exciting field for all of us and this field is constantly developing.
Regarding the transplantation, we as transplanters feel that transplantation still has a major role in all these indications. We feel that we need to develop personalized algorithms in order to fit in CAR-T and allogeneic transplantation and determine the best available option for each patient at each time. So we think that CAR-T is not an enemy of transplantation, but will help patients get into transplantation with a better status.